Your browser doesn't support javascript.
loading
Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?
Latorzeff, Igor; Sargos, Paul; Loos, Geneviève; Supiot, Stéphane; Guerif, Stéphane; Carrie, Christian.
Afiliação
  • Latorzeff I; Department of Oncology Radiotherapy, Bât Atrium, Clinique Pasteur, Toulouse, France.
  • Sargos P; Department of Radiotherapy, Institut Bergonié, Bordeaux, France.
  • Loos G; Department of Radiotherapy, Centre Jean-Perrin, Clermont-Ferrand, France.
  • Supiot S; Department of Radiotherapy, Institut de Cancérologie de L'Ouest René Gauducheau, Nantes, France.
  • Guerif S; Department of Radiotherapy, CHU de Poitiers, Poitiers, France.
  • Carrie C; Department of Radiotherapy, Centre Léon Bérard, Lyon, France.
Front Oncol ; 7: 108, 2017.
Article em En | MEDLINE | ID: mdl-28620579
ABSTRACT
For pathological high-risk prostate cancer, adjuvant irradiation has shown a survival benefit. Phase III studies have highlighted that half men would face biochemical relapse and would be candidate for radiotherapy at adjuvant or salvage times. Despite at least four published international contouring guidelines from different collaborative groups, discrepancies remain for volumes, delineation, and margins to be considered in order to optimize radiotherapy planning. This article from "Groupe d'Etude des Tumeurs UroGénitales (GETUG)" members will focus on controversies to help clinicians to create best volume delineation for adjuvant or salvage post prostatectomy radiotherapy.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article